Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Ductal Carcinoma In Situ (DCIS) Clinical Trials

A listing of Ductal Carcinoma In Situ (DCIS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (18) clinical trials

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01439711?term=CALGB+40903&rank=1

Phase

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

PRIMARY OBJECTIVES: I. To determine if treatment with a combination of metformin and doxycycline can increase the percentage of cells that express Caveolin-1 in the cancer associated fibroblasts of patients with breast, or uterine, and cervical cancers. SECONDARY OBJECTIVES: I. To determine the effect of metformin and doxycycline treatment on ...

Phase

Intraoperative Radiotherapy After Local Recurrence in Breast Cancer

Currently, the rate of ipsilateral breast tumor recurrence (IBTR) after breast- conserving surgery and radiotherapy remains at 10% at 10 years to 15% at 20 years, respectively. IBTR is an independent predictor of poor survival with a 3 to 4.6 increased risk of cancer-related death. In a heterogeneous population, local ...

Phase

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

OBJECTIVES There are two study components, 1) to evaluate the treatment response and toxicity of the protocol, and 2) to investigate the role of Magnetic Resonance Imaging (MRI) to monitor and predict the final pathological response. Objectives for treatment study component: 1.1 To estimate 2-year progression-free survival in patients with ...

Phase

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

This is a randomized, 3-arm, saline-controlled study involving women undergoing surgical management of DCIS. Forty-five (45) women who have been diagnosed with DCIS by core biopsy will receive intraductal administration of either carboplatin or normal saline (NS) into the DCIS-involved breast duct. Thirty (30) patients (i.e., 15 patients per arm) ...

Phase

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer.

Phase

Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

Despite advances in early detection and therapeutic options, unresectable or metastatic breast cancer remains incurable and is one of the leading causes of cancer-related mortality. Breast cancer is a molecularly heterogeneous disease. This study will be evaluating estrogen receptor (ER) expression positivity and/or progesterone receptor (PgR) positivity of breast cancer ...

Phase

The PROMISE Study: Duavee in Women With DCIS

PRIMARY OBJECTIVES; To determine if CE/BZA reduces proliferation as measured by Ki-67 protein expression Secondary Objectives: To determine if CE/BZA modulates expression of ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). To determine if CE/BZA modulates a previously validated set of epithelial markers of progression. To ...

Phase

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

PRIMARY OBJECTIVES: I. To evaluate 24 month breast photographic cosmetic scores with 9 fraction radiation compared to standard hypofractionation. SECONDARY OBJECTIVES: I. To evaluate Breast-Q patient reported outcomes (PROs) compared to historical control in breast conservation. II. To evaluate the incidence of acute and late radiation complications, based on Common ...

Phase

Ruxolitinib for Premalignant Breast Disease

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery ...

Phase